Strides Pharma Science Ltd - 532531 - Board Meeting Outcome for Intimation Of Scheme Of Arrangement, Pursuant To Regulation 30 Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations, 2015 (SEBI Listing Regulations)
Intimation of Scheme of Arrangement, pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (SEBI Listing Regulations) Strides Pharma Science Ltd - 532531 - Investor Call Link
Further to Company''s announcement on September 20, 2023, please find enclosed herewith Investor Call Link Strides Pharma Science Ltd - 532531 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Strides receives USFDA approval for Icosapent Ethyl Capsules Strides Pharma Science Ltd - 532531 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
We refer to Company's announcement of August 2, 2023 as part of Q1 FY24 Earnings Presentation about our intent to combine CDMO interests of the group to become one of India's top specialty pharmaceuticals CDMOs. We now wish to inform you that a board meeting of the Company is scheduled to be held on Monday, September 25, 2023 to consider the above proposal. The Company will also host a call on Monday, September 25, 2023 at 17:00 hrs IST to interact with the investors in connection with the above proposal. Strides Pharma Science Ltd - 532531 - Board Meeting Intimation for Scheme Of Arrangement
Strides Pharma Science Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 25/09/2023 ,inter alia, to consider and approve We refer to Company's announcement of August 2, 2023 as part of Q1 FY24 Earnings Presentation about our intent to combine CDMO interests of the group to become one of India's top specialty pharmaceuticals CDMOs. We now wish to inform you that a board meeting of the Company is scheduled to be held on Monday, September 25, 2023 to consider the above proposal. The Company will also host a call on Monday, September 25, 2023 at 17:00 hrs IST to interact with the investors in connection with the above proposal. Strides Pharma Science Ltd - 532531 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Strides receives tentative USFDA approval for Dolutegravir/ Lamivudine/ Tenofovir Disproxil Fumurate tablets
Strides Pharma up 4% as arm receives tentative USFDA approval for Dolutegravir tablets
The products will be manufactured at the company's facility in Bengaluru and conversion of this tentative approval to a full approval is expected upon expiry of the constraining patents. Strides Pharma Science Ltd - 532531 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Strides receives tentative USFDA approval for Dolutegravir tablets Strides Pharma Science Ltd - 532531 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Strides receives USFDA approval for Sevelamer Carbonate for Oral Suspension
Strides Pharma gains 6% as board gives nod to acquire 100% in Strides Pharma Services
The said transaction is to be completed by September 15, 2023.